Legend Biotech Corporation, a prominent player in cell therapy, disclosed the pricing for a public offering of 7,700,000 American Depositary Shares (ADSs), with each representing two ordinary shares, at a public price of $29.35 per ADS. The company has also given underwriters a 30-day option to buy up to an additional 1,155,000 ADSs at the same price, deducting underwriting discounts and commissions. All ADSs are offered by Legend Biotech. The company anticipates gross proceeds of about $226 million, excluding expenses, from this offering. The closing date for this transaction is set for June 23, 2026, subject to standard closing conditions.